ArticlePharmacoEconomics - open2026
Valuing Maintenance of Visual Function in Retinitis Pigmentosa: A Discrete Choice Experiment with Patients and the General Public.
Article in PharmacoEconomics - open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesRetinitis pigmentosa (RP) is a progressive and sight-threatening condition with few treatment options. Patients with RP experience variable progressive vision deterioration that can severely affect functioning. Currently, there is no published literature to indicate the preferences that patients with RP place on potential treatments. This study compared patient preferences to those of a sample from the general public.
methodsAn online, discrete choice experiment (DCE) elicited preferences of a United States (US) sample for maintaining visual function-related activities of daily living (VF-ADL). The data were stratified by sociodemographic and clinical characteristics. Participants completed best-/worst-choice tasks using predefined attributes and varying levels, including time to deterioration in mobility and ability to read associated with worsening visual function.
resultsA total of 150 patients with RP and 301 public participants completed the DCE. By the age of 32-40 years, VF-ADL deteriorated substantially in patients versus public (81% vs 13% reported lower combined mobility/ability to read). Patients with RP placed the greatest value on ability to get around (relative attribute importance [RAI] 51%; standard error [SE] 3.4; 95% confidence interval [CI] 45-58), whereas the public sample preferred ability to get information (RAI 48%; SE 4.7; 95% CI 39-57). Patients with RP placed less weight on extending life expectancy compared with public participants.
conclusionsPatients with RP demonstrated preferences in VF-ADL and life expectancy associated with deterioration in visual function and potential treatment benefits that differ from those of the public. Considering patient preferences is critical to understand disease burden and estimate the value of therapeutic interventions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.